Harrow’s Post

View organization page for Harrow, graphic

7,757 followers

Did you know that ILEVRO (nepafenac ophthalmic suspension) 0.3% has excellent market access coverage? With 74%* of all lives covered across commercial and Medicare Part D plans, doctors can confidently prescribe ILEVRO to their patients. Learn more about ILEVRO and its market access coverage today at www.ilevrohcp.com! *Data provided through MMIT and is current as of 2/2024. The information provided in this communication is not a guarantee of coverage or payment (partial or full). Actual benefits are determined by each plan administrator in accordance with its respective policy and procedures. Nothing herein may be construed as an endorsement, approval, recommendation, representation, or warranty of any kind by any plan or insurer referenced herein.

To view or add a comment, sign in

Explore topics